The same phenomenon occurred in our results: aPC therapy did not effectively activate T cells, increasing the proportion of CD8+ and memory T cells and allowing tumours to express higher levels of Th1 inflammatory factors and killer cytokines, which may be the reason for the poor treatment efficacy. Here, CD8A is linked to neoplasm.